Clinical Data Revolution rockets on strong pancreatic cancer data PharmaphorumRevolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib.Clinical DataOncologyRead full story pharminent April 14, 2026 (Last updated: April 14, 2026) Pharmaphorum Revolution Medicines thinks it could transform the treatment of pancreatic cancer based on phase 3 data with its pan-RAS(on) inhibitor daraxonrasib. Clinical DataOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priorityNext: Novo Nordisk and OpenAI forge alliance to drive speedy drug development Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
